Analysts Expect Nu Skin Enterprises, Inc. (NUS) Will Post Quarterly Sales of $662.26 Million
Analysts expect that Nu Skin Enterprises, Inc. (NYSE:NUS) will post sales of $662.26 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Nu Skin Enterprises’ earnings, with estimates ranging from $659.30 million to $667.66 million. Nu Skin Enterprises reported sales of $563.70 million in the same quarter last year, which would suggest a positive year over year growth rate of 17.5%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, November 7th.
According to Zacks, analysts expect that Nu Skin Enterprises will report full year sales of $2.65 billion for the current financial year. For the next fiscal year, analysts expect that the firm will report sales of $2.71 billion, with estimates ranging from $2.61 billion to $2.78 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Nu Skin Enterprises.
Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings results on Thursday, August 2nd. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.18. Nu Skin Enterprises had a return on equity of 25.67% and a net margin of 5.74%. The firm had revenue of $704.19 million during the quarter, compared to the consensus estimate of $642.16 million. During the same quarter in the prior year, the firm posted $0.77 EPS. The business’s revenue was up 28.0% on a year-over-year basis.
NYSE:NUS traded up $1.69 during trading hours on Wednesday, reaching $68.66. 429,264 shares of the stock were exchanged, compared to its average volume of 468,632. Nu Skin Enterprises has a twelve month low of $59.31 and a twelve month high of $88.68. The company has a quick ratio of 1.19, a current ratio of 1.82 and a debt-to-equity ratio of 0.46. The company has a market cap of $4.58 billion, a P/E ratio of 21.26, a price-to-earnings-growth ratio of 2.35 and a beta of 1.06.
In other news, insider Joseph Y. Chang sold 10,600 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $82.13, for a total value of $870,578.00. Following the completion of the sale, the insider now owns 63,416 shares of the company’s stock, valued at approximately $5,208,356.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edwina D. Woodbury sold 5,000 shares of the stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $85.02, for a total value of $425,100.00. Following the completion of the sale, the director now directly owns 11,860 shares of the company’s stock, valued at approximately $1,008,337.20. The disclosure for this sale can be found here. In the last three months, insiders sold 42,850 shares of company stock valued at $3,523,563. 3.00% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NUS. Global X Management Co LLC lifted its holdings in Nu Skin Enterprises by 141.9% during the 2nd quarter. Global X Management Co LLC now owns 1,732 shares of the company’s stock valued at $135,000 after purchasing an additional 1,016 shares during the last quarter. Quantbot Technologies LP increased its position in Nu Skin Enterprises by 293.0% during the 1st quarter. Quantbot Technologies LP now owns 2,071 shares of the company’s stock worth $152,000 after buying an additional 1,544 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Nu Skin Enterprises during the 2nd quarter worth $210,000. Greenleaf Trust bought a new position in Nu Skin Enterprises during the 2nd quarter worth $216,000. Finally, Stevens Capital Management LP bought a new position in Nu Skin Enterprises during the 2nd quarter worth $221,000. 76.00% of the stock is owned by institutional investors.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Recommended Story: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.